PATIENTS' PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

被引：1
|
作者：
Zeidan, A. [1 ]
Perepezko, K. [2 ]
Salimi, T. [3 ]
Washington, T. [3 ]
Epstein, R. [4 ]
机构：
[1] Yale Canc Ctr, Hematol, New Haven, CT USA
[2] CorEvitas Llc, Waltham, MA USA
[3] Taiho Oncol Inc, Princeton, NJ USA
[4] Epstein Hlth Llc, Woodcliff Lake, NJ USA
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107127
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O14
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Decitabine dosage in myelodysplastic syndromes
    Giagounidis, Aristoteles A. N.
    BLOOD, 2007, 110 (03) : 1082 - 1083
  • [22] Decitabine (Dacogen) for myelodysplastic syndromes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2006, 48 (1247): : 91 - 92
  • [23] Clinical Observation Of Decitabine Treatment In Selected Patients With Lower Risk Myelodysplastic Syndromes
    Chang, Chunkang
    Zhang, Zheng
    Zhao, Youshan
    Li, Xiao
    BLOOD, 2013, 122 (21)
  • [24] Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes
    Ding, Kai
    Fu, Rong
    Liu, Hui
    Nachnani, Deepak Anil
    Shao, Zong-Hong
    ONCOLOGY LETTERS, 2016, 11 (04) : 2347 - 2352
  • [25] Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very High-Risk Myelodysplastic Syndromes (MDS)
    Zeidan, Amer M.
    Mosher, Karen
    Souza, Sonia
    Mirakhur, Beloo
    Keer, Harold N.
    Taylor, Jason A.
    BLOOD, 2022, 140 : 9779 - 9780
  • [26] Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia
    Thota, Swapna
    Oganesian, Aram
    Azab, Mohammad
    Griffiths, Elizabeth A.
    FUTURE ONCOLOGY, 2021, 17 (16) : 2077 - 2087
  • [27] PHASE 2 STUDY OF ORAL DECITABINE AND CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Zeidan, A.
    Mosher, K.
    Souza, S.
    Mirakhur, B.
    Taylor, J.
    Keer, H.
    LEUKEMIA RESEARCH, 2023, 128
  • [28] An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
    Savona, Michael R.
    Odenike, Olatoyosi
    Amrein, Philip C.
    Steensma, David P.
    DeZern, Amy E.
    Michaelis, Laura C.
    Faderl, Stefan
    Harb, Wael
    Kantarjian, Hagop
    Lowder, James
    Oganesian, Aram
    Azab, Mohammad
    Garcia-Manero, Guillermo
    LANCET HAEMATOLOGY, 2019, 6 (04): : E194 - E203
  • [29] Oral decitabine-cedazuridine in acute myeloid leukaemia
    Bouligny, Ian M.
    Dinardo, Courtney D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 1674 - 1676
  • [30] Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
    Yun, John Paul
    Ding, Philip Q.
    Dolley, Aastha
    Cheung, Winson Y.
    CURRENT ONCOLOGY, 2023, 30 (09) : 8005 - 8018
12345